Accuprobe Awareness

The clinical presentation of COVID-19, varies from no symptoms to severe symptoms with complications like acute respiratory failure, acute respiratory distress syndrome, metabolic acidosis, coagulopathy, and septic shock. A full blood count is a routine, inexpensive and easy test that provides information about formed blood contents. Patients with severe COVID-19 disease present with increased leucocytosis, neutrophilia, lymphopenia, eosinopenia and thrombocytopenia than those with non-severe disease. Recently, reports on the feasibility of few new haematological parameters like, Neutrophil to Lymphocyte ratio (NLR) , Lymphocyte to Monocyte ratio (LMR) and Platelet to Lymphocyte ratio (PLR) in predicting prognosis in patients with SARS-CoV-2 infection have been published. The current study shows that these parameters may be a rapid, cost-effective, widely available, useful prognostic factor in the early screening of critical illness in patients with confirmed COVID-19. These parame

The SARS-CoV-2 IgG Antibody (COVID-19 IgG) test is intended for the qualitative detection of IgG antibodies to SARS-CoV-2 in human blood. The SARS-CoV-2 IgG test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection. Antibodies are proteins produced by the immune system in response to an infection and are specific to that particular infection. They are found in the blood. SARS-CoV-2 IgG Test may help identify if you were exposed to the virus that causes COVID-19 and, if so, whether or not your body has developed antibodies. Although having antibodies usually gives immunity from further infection, there is a lack of evidence on whether having antibodies means you are protected against reinfection with COVID-19 in future.  This antibody develops in most patients at around two weeks after infection and remains in the blood after you have recovered although we do not presently know how long it may persist. Resul